Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6754094 | 0.98 | GAA (0.43) | GAACREBBPKMT2AKDM4EALDH1A1 | |
| SCHEMBL5169014 | 0.83 | CREBBP (0.62) | GAACREBBPKMT2AKDM4EALDH1A1 | |
| SCHEMBL6651479 | 0.78 | CREBBP (0.57) | GAACREBBPKDM4EALDH1A1GFER | |
| SCHEMBL6651475 | 0.77 | CREBBP (0.40) | GAACREBBPKMT2AKDM4EALDH1A1 | |
| SCHEMBL6652419 | 0.75 | GAA (0.51) | GAACREBBPKMT2AKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL6649161 | 0.74 | GAA (0.50) | GAACREBBPKMT2AKDM4EALDH1A1 | |
| SCHEMBL6654641 | 0.73 | CREBBP (0.49) | GAACREBBPKMT2AALDH1A1ADRA1B | |
| SCHEMBL6651873 | 0.72 | GAA (0.64) | GAAKMT2AKDM4EALDH1A1GFER | |
| SCHEMBL5169560 | 0.71 | ALDH1A1 (0.61) | GAAKMT2AKDM4EALDH1A1GFER | |
| SCHEMBL6651342 | 0.70 | CREBBP (0.44) | GAACREBBPKMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6703404-B2 | NITRIC OXIDE SYNTHASE INHIBITORS | GRUENENTHAL GMBH (DE) | 2004-03-09 | — | — | US | claimed |
| US-20040023972-A1 | Use of substituted imidazo[1,2-a]-pyridin-, -pyrimidin-and-pyrazin-3-yl-amine derivatives in the preparation of medicaments for inhibiting NOS | GRUENENTHAL GMBH (DE) | 2004-02-05 | — | — | US | claimed |
| EP-1218378-B1 | TERT.-BUTYL-(7-METHYL-IMIDAZO[1,2-A]PYRIDINE-3-YL)-AMINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2003-04-23 | — | — | EP | claimed |
| US-20030022914-A1 | Tert.-butyl-(7-menthyl-imidazol [1,2-A] pyridin-3-yl)-amine derivatives | GRUENENTHAL GMBH . | 2003-01-30 | — | — | US | claimed |
| EP-1326613-B1 | USE OF SUBSTITUTED IMIDAZO 1,2-A]PYRIDINE-, IMIDAZO [1,2-A]PYRIMIDINE AND IMIDAZO [1,2-A]PYRAZINE-3-YL-AMINE DERIVATIVES FOR PRODUCING NOS-INHIBITING MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2004-06-02 | — | — | EP | disclosed |
| US-6703404-B2 | NITRIC OXIDE SYNTHASE INHIBITORS | GRUENENTHAL GMBH (DE) | 2004-03-09 | — | — | US | disclosed |
| US-20040023972-A1 | Use of substituted imidazo[1,2-a]-pyridin-, -pyrimidin-and-pyrazin-3-yl-amine derivatives in the preparation of medicaments for inhibiting NOS | GRUENENTHAL GMBH (DE) | 2004-02-05 | — | — | US | disclosed |
| EP-1218378-B1 | TERT.-BUTYL-(7-METHYL-IMIDAZO[1,2-A]PYRIDINE-3-YL)-AMINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2003-04-23 | — | — | EP | disclosed |
| US-20030022914-A1 | Tert.-butyl-(7-menthyl-imidazol [1,2-A] pyridin-3-yl)-amine derivatives | GRUENENTHAL GMBH . | 2003-01-30 | — | — | US | disclosed |
| EP-1218378-A2 | TERT.-BUTYL-(7-METHYL-IMIDAZO[1,2-A]PYRIDINE-3-YL)-AMINE DERIVATIVES | Grünenthal GmbH (DE) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001027109-A2 | TERT.-BUTYL-(7-METHYL-IMIDAZO[1,2-A]PYRIDINE-3-YL)-AMINE DERIVATIVES | Grünenthal GmbH (DE) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022914-A1 | Tert.-butyl-(7-menthyl-imidazol [1,2-A] pyridin-3-yl)-amine derivatives | TERT, BET1, TRPM7 | GAA 4508/4885CREBBP 1133/4885KMT2A 766/4885 |
| US-20040023972-A1 | Use of substituted imidazo[1,2-a]-pyridin-, -pyrimidin-and-pyrazin-3-yl-amine derivatives in the preparation of medicaments for inhibiting NOS | NOS1, PTGIS, NOS2 | GAA 536/4885CREBBP 1065/4885KMT2A 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.